Clinical Trial Update: Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients [Phase 4]

View source ↗

Summary

This document reports the results of a Phase 4 post-authorization safety study of LysaKare in adults with Gastroenteropancreatic neuroendocrine tumors, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors

Drugs mentioned

• LysaKare

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 4 | Status: COMPLETED | Results posted: 2025-01-24